Clin Cancer Res: Combination of famitinib, camrelizumab, and nab-paclitaxel for advanced triple-negative breast cancer

Camrelizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), in combination with nab-paclitaxel in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC) showed good antitumor activity
.
Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR and c-kit

The aim of this study was to evaluate the efficacy and safety of famitinib, camrelizumab, and nab-paclitaxel in the treatment of advanced immunomodulatory triple-negative breast cancer
.

Research Process

This is an open-label, single-arm, phase II study in previously untreated patients with advanced immunomodulatory triple-negative breast cancer (CD8 IHC staining ≥10%) treated with famitinib (20 mg, orally, Days 1 to 28), camrelizumab (200 mg IV, days 1 and 15), nab-paclitaxel (100 mg/m2, days 1, 8, and 15) days), 28 days as a course of treatment

Median progression-free survival and overall survival

A total of 48 patients were recruited and all received study treatment
.
After a median follow-up of 17.

Adverse reactions

Of the 30 patients who underwent IHC, 13 (43.

In conclusion, this triple regimen has good efficacy and is well tolerated in previously untreated advanced immunomodulatory triple-negative breast cancer
.
In addition, a randomized controlled clinical trial is underway to validate the findings of this study

Original source:

Li Chen; Yi-Zhou Jiang; Song-Yang Wu, et al.